vs
Envista Holdings Corp（NVST）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是Envista Holdings Corp的1.3倍（$961.0M vs $750.6M）。Envista Holdings Corp净利率更高（4.4% vs -15.2%，领先19.6%）。Envista Holdings Corp同比增速更快（15.0% vs 6.2%）。Envista Holdings Corp自由现金流更多（$91.7M vs $60.0M）。过去两年Envista Holdings Corp的营收复合增速更高（9.7% vs 0.4%）
Envista Holdings Corp是一家总部位于美国的企业，旗下Envista Forensics业务板块面向保险、法律及风险管理行业，在全球范围内提供法务工程与事故复原解决方案。公司前身为LWG咨询有限公司，2017年正式更名为Envista Forensics。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
NVST vs XRAY — 直观对比
营收规模更大
XRAY
是对方的1.3倍
$750.6M
营收增速更快
NVST
高出8.8%
6.2%
净利率更高
NVST
高出19.6%
-15.2%
自由现金流更多
NVST
多$31.7M
$60.0M
两年增速更快
NVST
近两年复合增速
0.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $750.6M | $961.0M |
| 净利润 | $32.9M | $-146.0M |
| 毛利率 | 54.7% | 46.1% |
| 营业利润率 | 9.8% | -14.5% |
| 净利率 | 4.4% | -15.2% |
| 营收同比 | 15.0% | 6.2% |
| 净利润同比 | 2641.7% | 66.0% |
| 每股收益（稀释后） | $0.20 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NVSTXRAY
| Q4 25 | $750.6M | $961.0M | ||
| Q3 25 | $669.9M | $904.0M | ||
| Q2 25 | $682.1M | $936.0M | ||
| Q1 25 | $616.9M | $879.0M | ||
| Q4 24 | $652.9M | $905.0M | ||
| Q3 24 | $601.0M | $951.0M | ||
| Q2 24 | $633.1M | $984.0M | ||
| Q1 24 | $623.6M | $953.0M |
净利润NVSTXRAY
| Q4 25 | $32.9M | $-146.0M | ||
| Q3 25 | $-30.3M | $-427.0M | ||
| Q2 25 | $26.4M | $-45.0M | ||
| Q1 25 | $18.0M | $20.0M | ||
| Q4 24 | $1.2M | $-430.0M | ||
| Q3 24 | $8.2M | $-494.0M | ||
| Q2 24 | $-1.2B | $-4.0M | ||
| Q1 24 | $23.6M | $18.0M |
毛利率NVSTXRAY
| Q4 25 | 54.7% | 46.1% | ||
| Q3 25 | 55.3% | 48.8% | ||
| Q2 25 | 54.2% | 52.4% | ||
| Q1 25 | 54.5% | 53.0% | ||
| Q4 24 | 57.1% | 49.3% | ||
| Q3 24 | 52.8% | 52.1% | ||
| Q2 24 | 51.6% | 51.9% | ||
| Q1 24 | 57.1% | 53.1% |
营业利润率NVSTXRAY
| Q4 25 | 9.8% | -14.5% | ||
| Q3 25 | 8.6% | -24.1% | ||
| Q2 25 | 6.8% | -13.7% | ||
| Q1 25 | 6.3% | 7.2% | ||
| Q4 24 | 7.1% | -56.2% | ||
| Q3 24 | 3.5% | -48.6% | ||
| Q2 24 | -182.2% | 5.1% | ||
| Q1 24 | 7.7% | 4.4% |
净利率NVSTXRAY
| Q4 25 | 4.4% | -15.2% | ||
| Q3 25 | -4.5% | -47.2% | ||
| Q2 25 | 3.9% | -4.8% | ||
| Q1 25 | 2.9% | 2.3% | ||
| Q4 24 | 0.2% | -47.5% | ||
| Q3 24 | 1.4% | -51.9% | ||
| Q2 24 | -181.9% | -0.4% | ||
| Q1 24 | 3.8% | 1.9% |
每股收益（稀释后）NVSTXRAY
| Q4 25 | $0.20 | $-0.74 | ||
| Q3 25 | $-0.18 | $-2.14 | ||
| Q2 25 | $0.16 | $-0.22 | ||
| Q1 25 | $0.10 | $0.10 | ||
| Q4 24 | $0.00 | $-2.09 | ||
| Q3 24 | $0.05 | $-2.46 | ||
| Q2 24 | $-6.69 | $-0.02 | ||
| Q1 24 | $0.14 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $326.0M |
| 总债务越低越好 | $1.4B | $2.3B |
| 股东权益账面价值 | $3.1B | $1.3B |
| 总资产 | $5.7B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.47× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资NVSTXRAY
| Q4 25 | $1.2B | $326.0M | ||
| Q3 25 | $1.1B | $363.0M | ||
| Q2 25 | $1.1B | $359.0M | ||
| Q1 25 | $1.1B | $398.0M | ||
| Q4 24 | $1.1B | $272.0M | ||
| Q3 24 | $991.3M | $296.0M | ||
| Q2 24 | $1.0B | $279.0M | ||
| Q1 24 | $948.5M | $291.0M |
总债务NVSTXRAY
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | $1.7B | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益NVSTXRAY
| Q4 25 | $3.1B | $1.3B | ||
| Q3 25 | $3.1B | $1.5B | ||
| Q2 25 | $3.1B | $2.0B | ||
| Q1 25 | $3.0B | $2.0B | ||
| Q4 24 | $2.9B | $1.9B | ||
| Q3 24 | $3.1B | $2.5B | ||
| Q2 24 | $3.0B | $3.1B | ||
| Q1 24 | $4.1B | $3.3B |
总资产NVSTXRAY
| Q4 25 | $5.7B | $5.4B | ||
| Q3 25 | $5.6B | $5.7B | ||
| Q2 25 | $5.7B | $6.1B | ||
| Q1 25 | $5.5B | $6.0B | ||
| Q4 24 | $5.4B | $5.8B | ||
| Q3 24 | $5.5B | $6.6B | ||
| Q2 24 | $5.4B | $6.9B | ||
| Q1 24 | $6.6B | $7.1B |
负债/权益比NVSTXRAY
| Q4 25 | 0.47× | 1.70× | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.48× | 0.90× | ||
| Q3 24 | 0.46× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $91.7M | $60.0M |
| 自由现金流率自由现金流/营收 | 12.2% | 6.2% |
| 资本支出强度资本支出/营收 | 2.2% | 4.3% |
| 现金转化率经营现金流/净利润 | 3.28× | — |
| 过去12个月自由现金流最近4个季度 | $230.4M | $104.0M |
8季度趋势，按日历期对齐
经营现金流NVSTXRAY
| Q4 25 | $108.0M | $101.0M | ||
| Q3 25 | $78.7M | $79.0M | ||
| Q2 25 | $88.7M | $48.0M | ||
| Q1 25 | $300.0K | $7.0M | ||
| Q4 24 | $132.4M | $87.0M | ||
| Q3 24 | $70.7M | $141.0M | ||
| Q2 24 | $93.1M | $208.0M | ||
| Q1 24 | $40.3M | $25.0M |
自由现金流NVSTXRAY
| Q4 25 | $91.7M | $60.0M | ||
| Q3 25 | $67.9M | $40.0M | ||
| Q2 25 | $76.4M | $16.0M | ||
| Q1 25 | $-5.6M | $-12.0M | ||
| Q4 24 | $123.8M | $36.0M | ||
| Q3 24 | $63.3M | $98.0M | ||
| Q2 24 | $86.3M | $156.0M | ||
| Q1 24 | $29.3M | $-9.0M |
自由现金流率NVSTXRAY
| Q4 25 | 12.2% | 6.2% | ||
| Q3 25 | 10.1% | 4.4% | ||
| Q2 25 | 11.2% | 1.7% | ||
| Q1 25 | -0.9% | -1.4% | ||
| Q4 24 | 19.0% | 4.0% | ||
| Q3 24 | 10.5% | 10.3% | ||
| Q2 24 | 13.6% | 15.9% | ||
| Q1 24 | 4.7% | -0.9% |
资本支出强度NVSTXRAY
| Q4 25 | 2.2% | 4.3% | ||
| Q3 25 | 1.6% | 4.3% | ||
| Q2 25 | 1.8% | 3.4% | ||
| Q1 25 | 1.0% | 2.2% | ||
| Q4 24 | 1.3% | 5.6% | ||
| Q3 24 | 1.2% | 4.5% | ||
| Q2 24 | 1.1% | 5.3% | ||
| Q1 24 | 1.8% | 3.6% |
现金转化率NVSTXRAY
| Q4 25 | 3.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.36× | — | ||
| Q1 25 | 0.02× | 0.35× | ||
| Q4 24 | 110.33× | — | ||
| Q3 24 | 8.62× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.71× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NVST
| Other | $375.8M | 50% |
| Specialty Productsand Technologies | $188.4M | 25% |
| Equipmentand Consumables | $186.4M | 25% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
